- 3.4Impact Factor
- 9.9CiteScore
- 20 daysTime to First Decision
Vaccines, Volume 13, Issue 5
May 2025 - 115 articles
Cover Story: Vaccines employing adenoviral (AdV) vector platforms such as human AdV (HAdV) and chimpanzee AdV (ChAdV) were pivotal in the fight against COVID-19. However, pre-existing vector immunity resulting from high natural prevalence and widespread use has limited their efficacy. The bovine AdV type 3 (BAdV-3) vector platform has emerged as a promising alternative in next-generation vaccine development. This platform offers key inherent attributes like high transduction efficiency, large transgene capacity, broad tissue tropism, suitability for intranasal administration, and strong innate and adaptive immune activation. Notably, it evades HAdV-specific immune responses and is nonpathogenic for its host. This review therefore explores the BAdV-3 vector’s potential as a versatile vaccine development platform for human and veterinary pathogens. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Articles
There are no articles in this issue yet.
Get Alerted
Add your email address to receive forthcoming issues of this journal.
Vaccines - ISSN 2076-393X